Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
|Articles|September 1, 2004
The American Journal of Managed Care
- September 2004
- Volume 10
- Issue 9
HMORN Abstracts
Advertisement
Cancer
Cardiovascular
Evaluating Care Delivery
Genetics
Health Economics
Information Technology
Lifestyle/Health Behavior
Pharmacoepidemiology
Prevention & Screening
Racial Disparities
Women's Health
Miscellaneous
Other
Articles in this issue
about 22 years ago
Consumers' Use of the Internet for Health Insuranceabout 22 years ago
Taking Stock at 2 Years - Continuing the Journeyabout 22 years ago
The Influence of Year-end Bonuses on Colorectal Cancer ScreeningAdvertisement
Related to this article
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
4
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
5